Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IGMS IGM Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: IGMS
Price (delayed)
$1.18
Market cap
$70.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.27
Enterprise value
$78.01M
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing
Highlights
IGMS's revenue is up by 27% year-on-year
IGM Biosciences's gross profit has increased by 27% YoY
IGM Biosciences's quick ratio has decreased by 30% YoY but it has increased by 10% QoQ
IGM Biosciences's debt has increased by 7% YoY but it has decreased by 2.7% from the previous quarter
IGM Biosciences's equity has plunged by 100% YoY and by 99% from the previous quarter
Key stats
What are the main financial stats of IGMS
Market
Valuations
Earnings
Shares outstanding
60.12M
Market cap
$70.94M
Enterprise value
$78.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
101.05
Price to sales (P/S)
26.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.1
Revenue
$2.68M
Gross profit
$2.68M
Operating income
-$209.5M
Net income
-$198.87M
EBIT
-$198.87M
EBITDA
-$184.68M
Free cash flow
-$146.46M
Per share
Balance sheet
Liquidity
EPS
-$3.27
EPS diluted
-$3.27
Free cash flow per share
-$2.39
Book value per share
$0.01
Revenue per share
$0.04
TBVPS
$3.38
Total assets
$206.89M
Total liabilities
$206.19M
Debt
$43.96M
Equity
$698,000
Working capital
$132.84M
Debt to equity
62.98
Current ratio
5.71
Quick ratio
5.39
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
-6,888.4%
Gross margin
100%
Net margin
-7,417.8%
Operating margin
-7,814.2%
Return on assets
-71.4%
Return on equity
-318%
Return on invested capital
-82.3%
Return on capital employed
-111.3%
Return on sales
-7,417.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IGMS stock price
How has the IGM Biosciences stock price performed over time
Intraday
2.61%
1 week
4.42%
1 month
-0.84%
1 year
-87.3%
YTD
-80.69%
QTD
2.61%
Financial performance
How have IGM Biosciences's revenue and profit performed over time
Revenue
$2.68M
Gross profit
$2.68M
Operating income
-$209.5M
Net income
-$198.87M
Gross margin
100%
Net margin
-7,417.8%
IGMS's operating margin is up by 35% year-on-year
IGM Biosciences's net margin has increased by 34% YoY
IGMS's revenue is up by 27% year-on-year
IGM Biosciences's gross profit has increased by 27% YoY
Price vs fundamentals
How does IGMS's price correlate with its fundamentals
Growth
What is IGM Biosciences's growth rate over time
Valuation
What is IGM Biosciences stock price valuation
P/E
N/A
P/B
101.05
P/S
26.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.1
The EPS is up by 24% year-on-year
IGM Biosciences's equity has plunged by 100% YoY and by 99% from the previous quarter
IGMS's price to sales (P/S) is 83% less than its last 4 quarters average of 162.7
IGMS's revenue is up by 27% year-on-year
Efficiency
How efficient is IGM Biosciences business performance
IGMS's return on equity has dropped by 194% year-on-year and by 67% since the previous quarter
The return on sales is up by 34% year-on-year
The ROA has contracted by 32% YoY and by 17% from the previous quarter
The return on invested capital has declined by 14% since the previous quarter and by 7% year-on-year
Dividends
What is IGMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IGMS.
Financial health
How did IGM Biosciences financials performed over time
The total assets has declined by 45% year-on-year and by 22% since the previous quarter
IGM Biosciences's quick ratio has decreased by 30% YoY but it has increased by 10% QoQ
IGM Biosciences's equity has plunged by 100% YoY and by 99% from the previous quarter
IGM Biosciences's debt has increased by 7% YoY but it has decreased by 2.7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.